1/13
09:18 am
ucbjy
PrBIMZELX® (bimekizumab injection) approved in Canada for treatment of moderate to severe hidradenitis suppurativa (HS) [Yahoo! Finance]
Low
Report
PrBIMZELX® (bimekizumab injection) approved in Canada for treatment of moderate to severe hidradenitis suppurativa (HS) [Yahoo! Finance]
12/8
07:00 am
ucbjy
UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduced countable motor seizure frequency in CDKL5 deficiency disorder
Low
Report
UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduced countable motor seizure frequency in CDKL5 deficiency disorder
12/4
08:12 am
ucbjy
UCB shares leading scientific research and advances at American Epilepsy Society Annual Meeting
Low
Report
UCB shares leading scientific research and advances at American Epilepsy Society Annual Meeting
11/5
07:32 am
ucbjy
UCB (OTCMKTS:UCBJY) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Low
Report
UCB (OTCMKTS:UCBJY) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
11/3
04:00 pm
ucbjy
U.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)
Low
Report
U.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)
10/29
12:00 pm
ucbjy
UCB opens applications for 2026 UCB Myasthenia Gravis Scholarship™
Low
Report
UCB opens applications for 2026 UCB Myasthenia Gravis Scholarship™
10/29
07:00 am
ucbjy
UCB to unveil new data for RYSTIGGO® (rozanolixizumab-noli) and ZILBRYSQ®(zilucoplan) for gMG at the 2025 AANEM Annual Meeting and MGFA Scientific Session
Low
Report
UCB to unveil new data for RYSTIGGO® (rozanolixizumab-noli) and ZILBRYSQ®(zilucoplan) for gMG at the 2025 AANEM Annual Meeting and MGFA Scientific Session
10/28
06:19 am
ucbjy
UCB (OTCMKTS:UCBJY) was upgraded by analysts at Jefferies Financial Group Inc. to a "moderate sell" rating.
Medium
Report
UCB (OTCMKTS:UCBJY) was upgraded by analysts at Jefferies Financial Group Inc. to a "moderate sell" rating.
10/25
11:00 am
ucbjy
BIMZELX® (bimekizumab-bkzx) Three-Year Rheumatology Data at ACR 2025 Demonstrated Sustained Inflammation Control in Psoriatic Arthritis and Axial Spondyloarthritis
Low
Report
BIMZELX® (bimekizumab-bkzx) Three-Year Rheumatology Data at ACR 2025 Demonstrated Sustained Inflammation Control in Psoriatic Arthritis and Axial Spondyloarthritis